The latest price target for Innate Pharma (NASDAQ:IPHA) was reported by HC Wainwright & Co. on December 9, 2024. The analyst firm set a price target for $11.50 expecting IPHA to rise to within 12 months (a possible 463.73% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Innate Pharma (NASDAQ:IPHA) was provided by HC Wainwright & Co., and Innate Pharma reiterated their buy rating.

There is no last upgrade for Innate Pharma

There is no last downgrade for Innate Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Innate Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Innate Pharma was filed on December 9, 2024 so you should expect the next rating to be made available sometime around December 9, 2025.

While ratings are subjective and will change, the latest Innate Pharma (IPHA) rating was a reiterated with a price target of $11.50 to $11.50. The current price Innate Pharma (IPHA) is trading at is $2.04, which is out of the analyst’s predicted range.